Joel Greenblatt Charles River Laboratories International, Inc. Transaction History

Gotham Asset Management, LLC

$10.2 Billion
Q4 2024

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 123,690 shares of CRL stock, worth $20.7 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

123,690

Previous 77,377 59.85%

Holding current value

$20.7 Million

Previous $15.2 Million 49.8%

% of portfolio

0.22%

Previous 0.16%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$178.58 - $220.69 $8.27 Million - $10.2 Million	46,313 Added 59.85%	123,690 $22.8 Million
Q3 2024 Nov 14, 2024	BUY	$187.96 - $245.29 $4.93 Million - $6.44 Million	26,254 Added 51.35%	77,377 $15.2 Million
Q2 2024 Aug 14, 2024	BUY	$206.39 - $268.73 $5.79 Million - $7.54 Million	28,064 Added 121.71%	51,123 $10.6 Million
Q1 2024 May 15, 2024	BUY	$203.52 - $273.43 $1.24 Million - $1.67 Million	6,093 Added 35.91%	23,059 $6.25 Million
Q4 2023 Feb 14, 2024	BUY	$164.52 - $238.84 $146,258 - $212,328	889 Added 5.53%	16,966 $4.01 Million
Q3 2023 Nov 14, 2023	BUY	$194.44 - $217.61 $358,547 - $401,272	1,844 Added 12.96%	16,077 $3.15 Million
Q2 2023 Aug 14, 2023	SELL	$183.71 - $210.25 $336,556 - $385,178	-1,832 Reduced 11.4%	14,233 $2.99 Million
Q1 2023 May 15, 2023	BUY	$191.89 - $259.92 $628,247 - $850,978	3,274 Added 25.6%	16,065 $3.24 Million
Q4 2022 Feb 14, 2023	SELL	$197.11 - $250.07 $535,744 - $679,690	-2,718 Reduced 17.53%	12,791 $2.79 Million
Q3 2022 Nov 14, 2022	SELL	$182.44 - $250.54 $285,153 - $391,594	-1,563 Reduced 9.16%	15,509 $3.05 Million
Q2 2022 Aug 15, 2022	SELL	$204.13 - $302.4 $431,122 - $638,668	-2,112 Reduced 11.01%	17,072 $3.65 Million
Q1 2022 May 16, 2022	BUY	$255.51 - $362.11 $3.67 Million - $5.2 Million	14,360 Added 297.68%	19,184 $5.45 Million
Q4 2021 Feb 14, 2022	SELL	$351.38 - $448.68 $609,292 - $778,011	-1,734 Reduced 26.44%	4,824 $1.82 Million
Q3 2021 Nov 15, 2021	BUY	$372.64 - $458.3 $472,507 - $581,124	1,268 Added 23.97%	6,558 $2.71 Million
Q2 2021 Aug 16, 2021	BUY	$294.17 - $371.65 $515,680 - $651,502	1,753 Added 49.56%	5,290 $1.96 Million
Q1 2021 May 17, 2021	SELL	$249.67 - $299.48 $863,109 - $1.04 Million	-3,457 Reduced 49.43%	3,537 $1.03 Million
Q4 2020 Feb 16, 2021	SELL	$222.0 - $252.62 $836,718 - $952,124	-3,769 Reduced 35.02%	6,994 $1.75 Million
Q3 2020 Nov 16, 2020	BUY	$175.56 - $226.45 $411,161 - $530,345	2,342 Added 27.81%	10,763 $2.44 Million
Q2 2020 Aug 13, 2020	SELL	$118.84 - $189.72 $2.38 Million - $3.81 Million	-20,059 Reduced 70.43%	8,421 $1.47 Million
Q1 2020 May 15, 2020	BUY	$98.9 - $178.34 $2.64 Million - $4.76 Million	26,665 Added 1469.15%	28,480 $3.59 Million
Q4 2019 Feb 14, 2020	BUY	$126.05 - $152.76 $228,780 - $277,259	1,815 New	1,815 $277,000
Q3 2019 Nov 14, 2019	SELL	$125.07 - $143.67 $281,157 - $322,970	-2,248 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$123.4 - $148.55 $970,294 - $1.17 Million	-7,863 Reduced 77.77%	2,248 $319,000
Q1 2019 May 15, 2019	SELL	$104.82 - $146.73 $2.49 Million - $3.49 Million	-23,794 Reduced 70.18%	10,111 $1.47 Million
Q4 2018 Feb 14, 2019	BUY	$105.09 - $137.23 $3.56 Million - $4.65 Million	33,905 New	33,905 $3.84 Million
Q2 2018 Aug 14, 2018	SELL	$102.37 - $117.25 $281,517 - $322,437	-2,750 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$98.19 - $115.2 $270,022 - $316,800	2,750 New	2,750 $294,000
Q4 2017 Feb 14, 2018	SELL	$100.43 - $118.09 $4.61 Million - $5.42 Million	-45,906 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$96.72 - $109.26 $4.44 Million - $5.02 Million	45,906	45,906 $4.96 Million

Others Institutions Holding CRL

# of Institutions

710

Shares Held

53.9M

Call Options Held

122K

Put Options Held

239K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $8.51B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account